Amgen, Inc. vs Bank of Nova Scotia — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Bank of Nova Scotia trades at $89.03 (market cap $108.32B). The key difference: Amgen, Inc. is far larger — about 2.1× Bank of Nova Scotia's market cap, and Bank of Nova Scotia pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| AMGN | BNS | |
|---|---|---|
Market Cap | $224.14B | $108.32B |
Sector | Health | Financials |
52-Week High | $417.20 | $90.29 |
52-Week Low | $271.18 | $56.41 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | 3.64% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →